Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors

Journal of Bone and Mineral Research

Volumn 21, Issue 4, 2006, Pages 536-542

  Roux, Christian ^a,l   Reginster, Jean Yves ^b   Fechtenbaum, Jacques ^a   Kolta, Sami ^a   Sawicki, Andrzej ^c   Tulassay, Zsolt ^d   Luisetto, Giovanni ^e   Padrino, José Maria ^f   Doyle, David ^g   Prince, Richard ^h   Fardellone, Patrice ⁱ   Sorensen, Ole Helmer ^j   Meunier, Pierre Jean ^k  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Warsawian Center of Osteoporosis and Calcium Metabolism   (Poland)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^e UNIVERSITY OF PADOVA   (Italy)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^h SIR CHARLES GAIRDNER HOSPITAL   (Australia)

ⁱ AMIENS UNIVERSITY HOSPITAL   (France)

^j HVIDOVRE HOSPITAL   (Denmark)

^k EDOUARD HERRIOT HOSPITAL   (France)

^l Cochin Hospital 27 ^*  (France)

more..

Author keywords

Osteoporosis; Risk factors; Strontium ranelate; Vertebral fracture

Indexed keywords

CALCIFEDIOL; CALCIUM ION; PLACEBO; STRONTIUM RANELATE; VITAMIN D;

AGE DISTRIBUTION; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL TRIAL; DRUG EFFICACY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; OSTEOPENIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; TREATMENT OUTCOME; VERTEBRA FRACTURE;

BONE DENSITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; SPINAL FRACTURES; THIOPHENES;

EID: 33645353336     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060101     Document Type: Article

References (24)

1. Cummings SR, Melton LJ 2002 Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767.
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
3. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91.
4. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
5. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
6. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
7. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340.
8. Marcus R, Wang O, Satterwhite J, Mitlak B 2003 The skeletal response to teriparatide is largely independent of age, initial bone density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18-23.
9. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ 1996 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517-523.
10. Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y 1993 An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8:607-615.
11. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R 2004 Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19:2012-2020.
12. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM. Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468.
13. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822.
14. Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC, Santora AC II, Black DM 2000 Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 48:241-249.
15. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D 2000 Risk of mortality following clinical fractures. Osteoporos Int 11:556-561.
16. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR 1998 The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann Intern Med 128:793-800.
17. Huang C, Ross PD, Wasnich RD 1996 Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 156:2469-2475.
18. Genant HK, Wu CY, Van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148.
19. Slosman D, Prowedini DM, Meunier PJ, Delmas PD, Sebert JL, De Vernejoul MC, Tsouderos Y, Reginster JY 1999 The use of different dual X-ray absorptiometry brands in a multicenter clinical trial. J Clin Densitom 2:37-44.
20. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M 2000 Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739.
21. Kotowicz MA, Melton LJ III, Cooper C, Atkinson EJ, O'Fallon WM, Riggs BL 1994 Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 9:599-605.
22. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E 2001 Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323.
23. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR 2003 Osteoporotic Fractures Research Group. BMD at multiple sites and risk of fracture of multiple types: Long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18:1947-1954.
24. Nielsen SP, Slosman D, Sorensen OH, Basse-Cathalinat B, De Cassin P, Roux CR, Meunier PJ 1999 Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom 2:371-379.